Review article: Biomarkers and personalised therapy in functional lower gastrointestinal disorders

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 7, 2015, Pages 818-828

  Camilleri, M ^a  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; ASIMADOLINE; BILE ACID; BILE ACID SEQUESTRANT; BISACODYL; COLESEVELAM; DEXLOXIGLUMIDE; ELOBIXIBAT; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; LINACLOTIDE; LUBIPROSTONE; NEUROTROPHIN; PEXACERFONT; PROBIOTIC AGENT; PRUCALOPRIDE; RELENOPRIDE; SOLABEGRON; TEGASEROD; VELUSETRAG; BIOLOGICAL MARKER;

BILE ACID DIARRHEA; BILE ACID MALABSORPTION; BIOLOGICAL FUNCTIONS; CELIAC DISEASE; CHRONIC CONSTIPATION; CLINICAL FEATURE; COLON MUCOSA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE MARKER; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE TRANSIT TIME; IRRITABLE COLON; NEUROIMAGING; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE DIAGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RECTUM MUCOSA; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; FEMALE; GASTROINTESTINAL DISEASES; IRRITABLE BOWEL SYNDROME; LOWER GASTROINTESTINAL TRACT; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES;

BILE ACIDS AND SALTS; BIOMARKERS; DIARRHEA; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; IRRITABLE BOWEL SYNDROME; LOWER GASTROINTESTINAL TRACT; MIDDLE AGED; PRECISION MEDICINE;

EID: 84940795258     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13351     Document Type: Review

References (64)

1. Lovell RM, Ford AC,. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-21.
2. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC,. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
3. Halder SL, Locke GR 3rd, Schleck CD, Zinsmeister AR, Melton LJ 3rd, Talley NJ,. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology 2007; 133: 799-807.
4. Camilleri M,. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2012; 367: 1626-35.
5. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
6. Barbara G, Stanghellini V,. Biomarkers in IBS: when will they replace symptoms for diagnosis and management? Gut 2009; 58: 1571-5.
7. Barbara G,. IBS: biomarkers for IBS: ready for prime time? Nat Rev Gastroenterol Hepatol 2015; 12: 9-10.
8. Corsetti M, Van Oudenhove L, Tack J,. The quest for biomarkers in IBS-where should it lead us? Neurogastroenterol Motil 2014; 26: 1669-76.
9. Sood R, Law GR, Ford AC,. Diagnosis of IBS: symptoms, symptom-based criteria, biomarkers or 'psychomarkers'? Nat Rev Gastroenterol Hepatol 2014; 11: 683-91.
10. Jones M, Chey WD, Singh S, et al,. A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. Aliment Pharmacol Ther 2014; 39: 426-37.
11. Camilleri M, Shin A, Busciglio I, et al,. Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neurogastroenterol Motil 2014; 26: 1677-85.
12. El-Salhy M, Hatlebakk JG, Gilja OH, Hausken T,. Densities of rectal peptide YY and somatostatin cells as biomarkers for the diagnosis of irritable bowel syndrome. Peptides 2015; 67: 12-9.
13. Pimentel M, Morales W, Rezaie A, et al,. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLoS ONE 2015; 10: e0126438.
14. Casén C, Vebø HC, Sekelja M, et al,. Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. Aliment Pharmacol Ther 2015; 42: 71-83.
15. Vazquez-Roque MI, Camilleri M, Smyrk T, et al,. A controlled trial of gluten-free diet in irritable bowel syndrome-diarrhea: effect on bowel frequency and intestinal functions. Gastroenterology 2013; 144: 903-11, e3.
16. Camilleri M, McKinzie S, Busciglio I, et al,. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008; 6: 772-81.
17. Viramontes BE, Camilleri M, McKinzie S, Pardi DS, Burton D, Thomforde GM,. Gender related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 92: 2671-6.
18. Mayer EA, Berman S, Derbyshire SW, et al,. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther 2002; 16: 1357-66.
19. Andresen V, Montori VM, Keller J, West C, Layer P, Camilleri M,. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and metaanalysis of randomized controlled trials. Clin Gastroenterol Hepatol 2008; 6: 545-55.
20. Highlights for prescribing Lotronex. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/021107s013lbl.pdf (accessed 29 July 2015).
21. Zucchelli M, Camilleri M, Andreasson AN, et al,. Association of TNFSF15 polymorphism with irritable bowel syndrome. Gut 2011; 60: 1671-7.
22. Swan C, Duroudier NP, Campbell E, et al,. Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα. Gut 2013; 62: 985-94.
23. Czogalla B, Schmitteckert S, Houghton LA, et al,. A meta-analysis of immunogenetic case-control association studies in irritable bowel syndrome. Neurogastroenterol Motil 2015; 27: 717-27.
24. Wouters MM, Lambrechts D, Knapp M, et al,. Genetic variants in CDC42 and NXPH1 as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome. Gut 2014; 63: 1401-9.
25. Ek WE, Reznichenko A, Ripke S, et al,. Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. Gut 2014; pii: gutjnl-2014-307997. doi: 10.1136/gutjnl-2014-307997 [Epub ahead of print].
26. Camilleri M, Carlson P, Acosta A, et al,. RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study. Am J Physiol 2014; 306: G1089-98.
27. Camilleri M, Carlson P, Acosta A, Busciglio IA,. Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion. Am J Physiol Gastrointest Liver Physiol 2015; 30: G10-20.
28. Videlock E, Mahurkar-Joshi S, Hoffman J, Shih W, Alberto M, Chang L,. Guanylate cyclase-C receptor and ligand expression in colonic mucosa in chronic constipation. Am J Gastroenterol 2014; 109: S540.
29. Camilleri M,. Intestinal secretory mechanisms in irritable bowel syndrome-diarrhea. Clin Gastroenterol Hepatol 2015; 13: 1051-7.
30. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA,. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006; 130: 34-43.
31. Dunlop SP, Coleman NS, Blackshaw E, et al,. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 349-57.
32. Camilleri M, Atanasova E, Carlson PJ, et al,. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002; 123: 425-32.
33. Garsed K, Chernova J, Hastings M, et al,. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut 2014; 63: 1617-25.
34. Li Y, Nie Y, Xie J, et al,. The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients. Dig Dis Sci 2007; 52: 2942-9.
35. Wong BS, Camilleri M, Carlson PJ, et al,. A klothoβ variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology 2011; 140: 1934-42.
36. Wong BS, Camilleri M, Carlson PJ, et al,. Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea. Dig Dis Sci 2012; 57: 1222-6.
37. Wong BS, Camilleri M, Eckert D, et al,. Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. Neurogastroenterol Motil 2012; 24: 358-65.
38. Hong JY, Kilpatrick LA, Labus JS, et al,. Sex and disease-related alterations of anterior insula functional connectivity in chronic abdominal pain. J Neurosci 2014; 34: 14252-9.
39. Irimia A, Labus JS, Torgerson CM, Van Horn JD, Mayer EA,. Altered viscerotopic cortical innervation in patients with irritable bowel syndrome. Neurogastroenterol Motil 2015; doi: 10.1111/nmo.12586 [Epub ahead of print]
40. Labus JS, Gupta A, Coveleskie K, et al,. Sex differences in emotion-related cognitive processes in irritable bowel syndrome and healthy control subjects. Pain 2013; 154: 2088-99.
41. Mayer EA, Gupta A, Kilpatrick LA, Hong JY,. Imaging brain mechanisms in chronic visceral pain. Pain 2015; 156 (Suppl. 1): S50-63.
42. Gupta A, Kilpatrick L, Labus J, et al,. Early adverse life events and resting state neural networks in patients with chronic abdominal pain: evidence for sex differences. Psychosom Med 2014; 76: 404-12.
43. Lowén MB, Mayer EA, Sjöberg M, et al,. Effect of hypnotherapy and educational intervention on brain response to visceral stimulus in the irritable bowel syndrome. Aliment Pharmacol Ther 2013; 37: 1184-97.
44. Drossman DA, Ringel Y, Vogt BA, et al,. Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. Gastroenterology 2003; 124: 754-61.
45. Han X, Tong J, Zhang J, et al,. Imipramine treatment improves cognitive outcome associated with enhanced hippocampal neurogenesis after traumatic brain injury in mice. J Neurotrauma 2011; 28: 995-1007.
46. Perera TD, Coplan JD, Lisanby SH, et al,. Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. J Neurosci 2007; 27: 4894-901.
47. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW,. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 1035-40.
48. 4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009; 104: 1831-43.
49. Ohman L, Simrén M,. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010; 7: 163-73.
50. Klooker TK, Braak B, Koopman KE, et al,. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010; 59: 1213-21.
51. Dunlop SP, Jenkins D, Neal KR, et al,. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2003; 18: 77-84.
52. Barbara G, Cremon C, Annese V, et al,. Randomised controlled trial of mesalazine in IBS. Gut 2014; pii: gutjnl-2014-308188. doi: 10.1136/gutjnl-2014-308188 [Epub ahead of print].
53. Lam C, Tan W, Leighton M, et al,. A multi-centre, parallel group, randomised placebo controlled trial of mesalazine for treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D). Gastroenterology 2014; 146: S123-4.
54. Manabe N, Wong BS, Camilleri M, Burton D, McKinzie S, Zinsmeister AR,. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil 2010; 22: 293-e82.
55. Sadik R, Stotzer PO, Simrén M, Abrahamsson H,. Gastrointestinal transit abnormalities are frequently detected in patients with unexplained GI symptoms at a tertiary centre. Neurogastroenterol Motil 2008; 20: 197-205.
56. Deiteren A, Camilleri M, Bharucha AE, et al,. Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. Neurogastroenterol Motil 2010; 22: 415-23.
57. Törnblom H, Van Oudenhove L, Sadik R, Abrahamsson H, Tack J, Simrén M,. Colonic transit time and IBS symptoms: what's the link? Am J Gastroenterol 2012; 107: 754-60.
58. Wedlake L, A'Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ,. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2009; 30: 707-17.
59. Valentin N, Camilleri M, Altayar O, et al,. Biomarkers for bile acid diarrhea in functional bowel disorder with diarrhea: a systematic review and meta-analysis. Gut 2015; in press
60. Camilleri M,. Scintigraphic biomarkers for colonic dysmotility. Clin Pharmacol Ther 2010; 87: 748-53.
61. Wilcox C, Turner J, Green J,. Systematic review: the management of chronic diarrhoea due to bile acid malabsorption. Aliment Pharmacol Ther 2014; 39: 923-39.
62. Camilleri M, Acosta A, Busciglio I, et al,. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2015; 41: 438-48.
63. Walters JR, Johnston IM, Nolan JD, Vassie C, Pruzanski ME, Shapiro DA,. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol Ther 2015; 41: 54-64.
64. Camilleri M,. The role of pharmacogenetics in nonmalignant gastrointestinal diseases. Nat Rev Gastroenterol Hepatol 2012; 9: 173-84.